STAT+: Sanofi, Regeneron expand partnership after Dupixent success — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Sanofi is paying Regeneron $1 billion upfront to co-develop new antibodies targeting immunological diseases, with possible milestone payments of up to $7 billion more on the table.
- Regeneron will lead research and development on the new antibodies while Sanofi spearheads commercial efforts, and the two companies will divide profits evenly.
- George Yancopoulos, Regeneron's chief scientific officer, framed the deal as a way to "deliver the next wave of innovation in immunology" by pairing Regeneron's antibody discovery capabilities with Sanofi's global reach.
- Dupixent — the existing Sanofi-Regeneron drug for immunological conditions — was described as "hugely successful" in the announcement and serves as the foundation for the expanded collaboration.
- The new antibodies extend a partnership structure in which Regeneron discovers and develops while Sanofi markets, mirroring the arrangement that produced Dupixent.
Why it matters: The deal commits up to $8B to extend a Dupixent-tested playbook to a fresh slate of immunology antibodies. Sanofi gains more candidates to commercialize globally; Regeneron secures continued R&D funding under an unchanged split of labor that previously produced the hugely successful Dupixent.
Ask SkimNews
